A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  American Journal of Kidney Diseases

• Publication date

  1999-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0272-6386(99)70221-0PMID 10196011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia

  2004cited by this paper
• RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.

  1999cited by this paper
• Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.

  1997cited by this paper
• [A study of aortic calcification uremia].

  1997cited by this paper
• Hyperparathyroidism in the hemodialysis population: a survey of 612 patients.

  1997cited by this paper
• RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.

  1997cited by this paper
• Arteriosclerosis in Dialysis Patients

  1996cited by this paper
• Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group.

  1996cited by this paper
• Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients?

  1996cited by this paper
• Predominance of aortic calcification as an atherosclerotic manifestation in women: the Reykjavik study.

  1996cited by this paper
• Prognostic significance of cardiac cinefluoroscopy for coronary calcific deposits in asymptomatic high risk subjects.

  1994cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Parathyroid gland function in chronic renal failure.

  1993cited by this paper
• Calcium acetate control of serum phosphorus in hemodialysis patients.

  1991cited by this paper
• Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate.

  1991cited by this paper
• Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy.

  1990cited by this paper
• Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.

  1989cited by this paper
• A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III.

  1988cited by this paper
• Fluids and electrolytes

  1986cited by this paper
• Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.

  1986cited by this paper
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

  1984cited by this paper
• Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemic agents: colestipol and clofibrate.

  1983cited by this paper
• Hypercalcaemic osteomalacia due to aluminium toxicity.

  1982cited by this paper
• The validity of a telephone-administered 24-hour dietary recall methodology.

  1982cited by this paper
• The dialysis encephalopathy syndrome. Possible aluminum intoxication.

  1976cited by this paper
• STARCH EMBOLI IN TRANSPLANTED KIDNEYS

  1974cited by this paper
• Seasonal Changes in Human Plasma Levels of 25-Hydroxyvitamin D

  1974cited by this paper
• SECONDARY HYPERPARATHYROIDISM AND RENAL OSTEO‐DYSTROPHY IN CHRONIC RENAL FAILURE: ANALYSIS OF 195 PATIENTS, WITH OBSERVATIONS ON THE EFFECTS OF CHRONIC DIALYSIS, KIDNEY TRANSPLANTATION AND SUBTOTAL PARATHYROIDECTOMY

  1969cited by this paper
• Arterial calcification and gangrene in uremia.

  1969cited by this paper
• Chronic calcium carbonate therapy in uremia.

  1969cited by this paper

• Effectiveness of Novel versus Conventional Phosphate Binder in Managing Hyperphosphatemia in Chronic Kidney Disease

  2025cites this paper
• Cinacalcet Efficacy in Hyperparathyroidism—Chronic Kidney Disease—Non-Dialysis, Hemodialysis, Peritoneal Dialysis, Kidney Transplantation: Critical Review

  2025cites this paper
• Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

  2025cites this paper
• Association of Sevelamer Initiation with Gastrointestinal Bleeding Hospitalization in Individuals Requiring Hemodialysis

  2024cites this paper
• Role of Nutrients in Pediatric Non-Dialysis Chronic Kidney Disease: From Pathogenesis to Correct Supplementation

  2024cites this paper
• Recommended calcium intake in adults and children with chronic kidney disease - a European consensus statement.

  2023cites this paper
• Study on the Effect of Low Calcium Dialysate on Biochemical Profile of Adynamic Bone Disease in Patients on Maintenance Hemodialysis

  2023cites this paper
• Effect of sevelamer on serum phosphorus levels in chronic kidney disease and hemodialysis patients; a systematic review and meta-analysis

  2023cites this paper
• Treatment for secondary hyperparathyroidism focusing on parathyroidectomy

  2023cites this paper
• Past, Present, and Future of Phosphate Management

  2022cites this paper
• New Directions in Phosphorus Management in Dialysis.

  2022cites this paper
• Phosphate Frustration: Treatment Options to Complement Current Therapies

  2022cites this paper
• EOS789, pan‐phosphate transporter inhibitor, ameliorates the progression of kidney injury in anti‐GBM‐induced glomerulonephritis rats

  2022cites this paper
• Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia

  2021cites this paper
• Management of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical options

  2021cites this paper
• Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review

  2021cites this paper
• The Outpatient Prescribing Pattern of Sevelamer in Al Seih

  2021cites this paper
• Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease

  2020cites this paper
• OP-NDTJ200157 1..8

  2020cites this paper
• Severe Hypocalcemia after Total Parathyroidectomy Plus Autotransplantation for Secondary Hyperthyroidism-Risk Factors and a Clinical Algorithm

  2020cites this paper
• Strategies for Phosphate Control in Patients With CKD

  2019cites this paper
• Mineral Bone Disorders in Chronic Kidney Disease

  2019cites this paper
• Chitosan‐Fe (III) Complex as a Phosphate Chelator in Uraemic Rats: A Novel Treatment Option

  2018cites this paper
• Parathyroidectomy in the Management of Secondary Hyperparathyroidism.

  2018cites this paper
• Prevalence and risk factors for hypercalcemia among non-dialysis patients with chronic kidney disease-mineral and bone disorder

  2018cites this paper
• Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

  2018cites this paper
• Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder

  2017cites this paper
• Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis

  2017cites this paper
• Investigating the role of hyperparathyroidism in the cardiovascular burden of chronic kidney disease

  2017cites this paper
• Renale Osteopathie

  2017cites this paper
• Molecular mediators and controlling mechanism of vascular calcification

  2017cites this paper
• Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

  2017cites this paper
• Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open‐label, multicentre, 12‐week phase III study

  2017cites this paper
• Calcium Homeostasis in Health and in Kidney Disease.

  2016cites this paper
• The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis

  2016cites this paper
• Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.

  2016influential citation
• Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients

  2016cites this paper
• An Update on Phosphate Binders: A Dietitian's Perspective.

  2016cites this paper
• Original Investigation The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial

  2015cites this paper
• Advances in pharmacotherapy for hyperphosphatemia in renal disease

  2015cites this paper
• Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia

  2015cites this paper
• The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.

  2015cites this paper
• Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials

  2015cites this paper
• New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials

  2015cites this paper
• Management of Chronic Kidney Disease in Children

  2015cites this paper
• The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review

  2015cites this paper
• Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

  2014cites this paper
• Iron uptake and ferrokinetics in healthy male subjects of an iron-based oral phosphate binder (SBR759) labeled with the stable isotope (58)Fe.

  2014cites this paper
• Therapeutic Class Overview Attention Deficit/Hyperactivity Disorder (ADHD) Agents and Stimulants

  2014cites this paper
• Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D.

  2014cites this paper
• [Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent].

  2014cites this paper
• Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis

  2014cites this paper
• Utilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease

  2013cites this paper
• Chronic kidney disease: mineral and bone disorder in children.

  2013cites this paper
• Role of hyperphosphatemia-mediated vascular calcification in cardiovascular outcomes and its management: a review.

  2013cites this paper
• [Clinical protocol and therapeutic guidelines for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease].

  2013cites this paper
• Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease

  2013cites this paper
• THE SAFETY AND EFFICACY OF PHOSPHATE BINDERS IN DIALYSIS PATIENTS

  2013cites this paper
• Body composition and function in chronic kidney disease

  2013cites this paper
• Efficacy and safety of lanthanum carbonate on chronic kidney disease–mineral and bone disorder in dialysis patients: a systematic review

  2013cites this paper
• Emerging Effects of Sevelamer in Chronic Kidney Disease

  2013cites this paper
• Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.

  2013cites this paper
• Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease–mineral bone disorders (CKD-MBD) in children

  2013cites this paper
• Cardiovascular effects of sevelamer in stage 3 CKD.

  2013cites this paper
• Sevelamer carbonate experience in Indian end stage renal disease patients

  2012cites this paper
• Chronic Kidney Disease Mineral and Bone Disorder

  2012cites this paper
• Hyperphosphataemia in Renal Failures

  2012cites this paper
• Diagnosis and Management of Renal Osteodystrophy in Children

  2012cites this paper
• Calcium builds strong bones, and more is better--correct? Well, maybe not.

  2012cites this paper
• Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.

  2011cites this paper
• The Phosphate Binder Equivalent Dose

  2011cites this paper
• Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

  2011cites this paper
• Vascular Calcification in Patients with Chronic Kidney Disease: Types, Clinical Impact and Pathogenesis

  2011cites this paper
• STUDY OF LIPID PROFILE OF PATIENTS RECEIVING SEVELAMER VS. OTHER PHOSPHATE BINDER

  2011cites this paper
• Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure.

  2011cites this paper
• A Review of Sevelamer Hydrochloride in End-Stage Renal Disease Patients on Dialysis

  2011cites this paper
• Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III – V)

  2010cites this paper
• Impact of phosphate binder type on coronary artery calcification in hemodialysis patients.

  2010cites this paper
• A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.

  2010cites this paper
• The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol

  2010cites this paper
• Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study.

  2010cites this paper
• What are phosphate binders and how do they work

  2010cites this paper
• Meta-Analysis Comparing Sevelamer and Calcium-Based Phosphate Binders on Cardiovascular Calcification in Hemodialysis Patients

  2010cites this paper
• Hypothesis: calcium carbonate as phosphate binder--the fallacy of relying on serum phosphorus.

  2010cites this paper
• Uncrushed residual tablets of Lanthanum carbonate in the intestine

  2010cites this paper
• Pharmacotherapy of end-stage renal disease

  2010cites this paper
• Effect of Sevelamer Hydrochloride on Bone in Experimental Uremic Rats

  2009cites this paper
• Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

  2009cites this paper
• Phosphate Binders in Chronic Kidney Disease and End‐Stage Renal Disease: A Patient‐Centered Approach

  2009cites this paper
• Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: Can we influence patient‐level outcomes?

  2009cites this paper
• Management of Chronic Kidney Disease

  2009cites this paper
• Impact of prescription benefit coverage limits on sevelamer hydrochloride adherence for patients with ESRD.

  2009cites this paper
• Carbonato de sevelámero: un fármaco prometedor

  2009cites this paper
• Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation.

  2009cites this paper
• Oral phosphate binders for the management of serum phosphate levels in dialysis patients.

  2009cites this paper
• Renal secondary hyperparathyroidism in dogs.

  2009cites this paper
• Oral phosphate binders.

  2009cites this paper
• Ipofosforemia e iperfosforemia

  2009cites this paper
• Uso do cloridrato de sevelamer e carbonato de cálcio na hiperfosfatemia de pacientes em hemodiálise Use of sevelamer hydrochloride and calcium carbonate in the control of hyperphosphatemia in patients in hemodialysis

  2009cites this paper
• Treatment Options for Hyperphosphatemia in Feline CKD: What's Out there?

  2009cites this paper